Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: Implications for dosing recommendations

Pediatric Infectious Disease Journal

Volumn 33, Issue 12, 2014, Pages 1231-1233

  Waal, Reneé De ^a   Kroon, S Max ^b   Holgate, Sandi L ^c   Horn, Alan R ^b   Tooke, Lloyd J ^b   Norman, Jennifer ^a   Smith, Peter ^a   Blockman, Marc ^a   Cotton, Mark F ^c   McIlleron, Helen M ^a   Cohen, Karen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Nevirapine; Preterm and low birth weight infants; Prevention of mother to child transmission of HIV; Therapeutic drug monitoring

Indexed keywords

ALANINE AMINOTRANSFERASE; NEVIRAPINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PETECHIA; POLYMERASE CHAIN REACTION; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; SIDE EFFECT; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

EID: 84964199882     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000453     Document Type: Article

References (11)

1. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: WHO Press; 2013.
2. South Africa Department of Health, South African National AIDS Council. The South African Antiretroviral Treatment Guidelines. Pretoria: National Department of Health; 2013.
3. Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003;192:37-48.
4. Boehinger Ingelheim Pharmaceuticals Inc. Full Prescribing Information: Viramune. USA: Boehinger Ingelheim Pharmaceuticals Inc.; 2012.
5. World Health Organisation. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach. Geneva: WHO Press; 2010.
6. Koup RA, Merluzzi VJ, Hargrave KD, et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepine BI-RG-587. J Infect Dis. 1991;163:966-970.
7. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 1998;178:368-374.
8. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
9. Shetty AK, Coovadia HM, Mirochnick MM, et al.; HIVNET 023 Study Team. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr. 2003;34:482-490.
10. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
11. la Porte C J L, Back DJ, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther. 2006;3:4-12.